DCOY - Salarius Pharmaceuticals, Inc.

5.84
-0.050   -0.856%

Share volume: 2,491
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$5.89
-0.05
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
9%
Profitability 8%
Dept financing 3%
Liquidity 58%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.52%
1 Month
-21.82%
3 Months
678.15%
6 Months
59.13%
1 Year
786.19%
2 Year
42.79%
Key data
Stock price
$5.84
P/E Ratio 
0.00
DAY RANGE
$5.79 - $5.90
EPS 
-$4.81
52 WEEK RANGE
$0.43 - $9.09
52 WEEK CHANGE
$712.24
MARKET CAP 
1.871 M
YIELD 
N/A
SHARES OUTSTANDING 
5.862 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-12-2025
BETA 
1.66
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$12,072
AVERAGE 30 VOLUME 
$30,577
Company detail
CEO: David J. Arthur
Region: US
Website: salariuspharma.com
Employees: 20
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company is headquartered in Houston, Texas.

Recent news